title: Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
abstract: Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but three recovered from all cytopenias. The median lymphocyte count at 6 months and 1 year was 11.51 × 10(9)/L and 6.9 × 10(9)/L, respectively. Median progression-free survival (PFS) was 8.25 years. The 5-year and 10-year overall survival (OS) rates were 84% and 67%, respectively. Histological transformation occurred in 11% of patients, and was the only parameter significantly associated with a shorter time to progression (p = 0.0001). Significant prognostic factors for OS were age (p = 0.0356) and histological transformation (p = 0.0312). In this large retrospective cohort, we confirmed that splenectomy as first-line treatment in patients with SMZL corrected cytopenias and lymphocytosis within the first year and was associated with a good PFS.
authors.affiliation: Service d'Hémato-Oncologie.
authors.forename: Julien
authors.initials: J
authors.lastname: Lenglet
authors.forename: Catherine
authors.initials: C
authors.lastname: Traullé
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Claire
authors.initials: C
authors.lastname: Benet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Munoz-Bongrand
authors.forename: Sandy
authors.initials: S
authors.lastname: Amorin
authors.forename: Maria-Elena
authors.initials: ME
authors.lastname: Noguera
authors.forename: Alexandra
authors.initials: A
authors.lastname: Traverse-Glehen
authors.forename: Martine
authors.initials: M
authors.lastname: Ffrench
authors.forename: Lucile
authors.initials: L
authors.lastname: Baseggio
authors.forename: Pascale
authors.initials: P
authors.lastname: Felman
authors.forename: Evelyne
authors.initials: E
authors.lastname: Callet-Bauchu
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.forename: Françoise
authors.initials: F
authors.lastname: Berger
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.forename: Josette
authors.initials: J
authors.lastname: Brière
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D016896:Treatment Outcome
keywords: Splenic marginal zone lymphoma; splenectomy; treatment